Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 4/20 | 0.43 |
| ▸ | CATSPER1 | Q8NEC5 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.40 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.40 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316479 | 0.84 | PTPN1 (0.49) | PTPN1POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL10994126 | 0.81 | RAB9A (0.55) | POLBALDH1A1RAB9AMAPTKMT2A | |
| SCHEMBL11794140 | 0.80 | SRD5A2 (0.40) | MAPK1ALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1753233 | 0.78 | TARBP2 (0.46) | PTPN1POLBMAPK1ALDH1A1RAB9A | |
| SCHEMBL280055 | 0.77 | PTPN1 (0.54) | PTPN1ALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL279943 | 0.76 | PTPN1 (0.53) | PTPN1POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL328123 | 0.74 | PTPN1 (0.54) | PTPN1POLBALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL11523311 | 0.72 | GPX4 (0.42) | ALDH1A1RAB9ASMN1; SMN2MAPTHPGD | |
| SCHEMBL11521735 | 0.72 | GPX4 (0.42) | ALDH1A1RAB9ASMN1; SMN2MAPTHPGD | |
| SCHEMBL12087977 | 0.71 | KMT2A (0.39) | PTPN1ALDH1A1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-4061651-A | Preparation of 3,5-disubstituted-4-nitroisoxazoles | TEXACO INC. (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | PTPN1 1416/4885POLB 4329/4885MAPK1 950/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | PTPN1 1463/4885POLB 4323/4885MAPK1 995/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | PTPN1 1638/4885POLB 4352/4885MAPK1 474/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | PTPN1 1416/4885POLB 4329/4885MAPK1 950/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | PTPN1 1416/4885POLB 4329/4885MAPK1 950/4885 |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | MPL, TEK, THPO | PTPN1 1493/4885POLB 3683/4885MAPK1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.